Kaiser Permanente is leading the charge in sustainable healthcare, from achieving carbon-neutral status to building net-zero energy facilities, all while addressing the growing health risks posed by climate change—an urgent mission that could reshape the future of patient care.

Ultragenyx reveals promising interim Phase 1/2 data showing rapid, multi-domain improvements in patients with Angelman syndrome treated with GTX-102, offering new hope for a disease that currently lacks any approved treatment—find out more about these groundbreaking results and what’s next in their development.